Loading...
•
Sep 30, 2023
Editas Q3 2023 Earnings Report
Editas Medicine's financial performance and business progress were reported for Q3 2023.
Key Takeaways
Editas Medicine reported a net loss of $45.0 million, or $0.55 per share, for the third quarter of 2023. The company's cash, cash equivalents, and marketable securities totaled $446.4 million as of September 30, 2023, which is expected to fund operations into the third quarter of 2025. Collaboration and other research and development revenues increased to $5.3 million due to an upfront payment from Vor Bio.
Advanced EDIT-301 clinical program, continuing patient enrollment and dosing.
Expects EDIT-301 to be a clinically differentiated, one-time, durable medicine.
Plans to share clinical data from RUBY and EdiTHAL trials at ASH and in a Company-sponsored webinar in December.
Appointed Caren Deardorf as Chief Commercial and Strategy Officer.
Revenue by Segment
Forward Guidance
Editas Medicine expects its cash, cash equivalents and marketable securities to fund operating expenses and capital expenditures into the third quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...